Bill Ackman of Pershing Square Capital Management says embattled drug maker Valeant is weeks away from hiring a new chief executive to oversee the company's turnaround.
Bill Ackman of Pershing Square Capital Management says embattled drug maker Valeant is weeks away from hiring a new chief executive to oversee the company's turnaround.
0 commentaires:
Enregistrer un commentaire